MoonLake Immunotherapeutics
MLTX· Manufacturing· Fiscal year ends in December
Dr. Jorge Santos da Silva is the CEO of MoonLake Immunotherapeutics and was paid $4.9M in FY2025 (Dec), up 252%.
Executives3
See all- 1Dr. Jorge Santos da SilvaChief Executive Officer and Interim Chair of the BoardFY2025
- 2Dr. Kristian ReichChief Scientific OfficerFY2025
- 3Matthias BodenstedtChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMoonLake Immunotherapeutics paid its 3 named executives $14.4M in total in FY2025 (Dec). CEO Dr. Jorge Santos da Silva was paid $4.9M of that.
| Name | |||
|---|---|---|---|
| Dr. Jorge Santos da SilvaChief Executive Officer and Interim Chair of the Board | |||
| Dr. Kristian ReichChief Scientific Officer | |||
| Matthias BodenstedtChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers15
See allThe FY2025 (Dec) proxy of MoonLake Immunotherapeutics names 15 peer companies for pay. Among MoonLake Immunotherapeutics and these peers, CEO pay was the lowest of 6 and total shareholder return was 4th highest of 6.
6th highest of 6in MoonLake Immunotherapeutics and its pay peers, FY2025 (Dec) by CEO pay:
4th highest of 6in MoonLake Immunotherapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Andrew Phillips, Ph.D.Director · 3 yr on the boardIndependentAudit, Compensation (Chair), Nominating (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 21, 2026 | FY2025 |
| Annual report | 10-K | Feb 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Feb 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 24, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
